Stable and soluble antibodies inhibiting VEGF
US10590193B2 · kind B2 · utility
5Cited by
47References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 16, 2017 |
| Grant date | Mar 17, 2020 |
| Priority date | — |
| Expiry date | Nov 16, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to soluble and stable anti-VEGF imunobinders comprising CDRs from rabbit monoclonal antibodies. Said antibodies are designed for the diagnosis and/or treatment of VEGF-mediated disorders. The hybridomas, nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.